BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21790289)

  • 1. Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.
    Sargent JL; Whitfield ML
    Expert Rev Clin Immunol; 2011 Jul; 7(4):463-73. PubMed ID: 21790289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis.
    Moon SJ; Bae JM; Park KS; Tagkopoulos I; Kim KJ
    Ann Rheum Dis; 2019 Jun; 78(6):817-825. PubMed ID: 30952646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profibrotic Activation of Human Macrophages in Systemic Sclerosis.
    Bhandari R; Ball MS; Martyanov V; Popovich D; Schaafsma E; Han S; ElTanbouly M; Orzechowski NM; Carns M; Arroyo E; Aren K; Hinchcliff M; Whitfield ML; Pioli PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1160-1169. PubMed ID: 32134204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?
    Assassi S; Mayes MD
    Curr Opin Rheumatol; 2013 Nov; 25(6):686-91. PubMed ID: 24061076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures.
    Dolcino M; Pelosi A; Fiore PF; Patuzzo G; Tinazzi E; Lunardi C; Puccetti A
    Front Immunol; 2018; 9():449. PubMed ID: 29559981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-beta in systemic sclerosis (scleroderma).
    Varga J; Whitfield ML
    Front Biosci (Schol Ed); 2009 Jun; 1(1):226-35. PubMed ID: 19482698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subsets in the gene expression signatures of scleroderma skin.
    Milano A; Pendergrass SA; Sargent JL; George LK; McCalmont TH; Connolly MK; Whitfield ML
    PLoS One; 2008 Jul; 3(7):e2696. PubMed ID: 18648520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts.
    Johnson ME; Mahoney JM; Taroni J; Sargent JL; Marmarelis E; Wu MR; Varga J; Hinchcliff ME; Whitfield ML
    PLoS One; 2015; 10(1):e0114017. PubMed ID: 25607805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.
    Sargent JL; Li Z; Aliprantis AO; Greenblatt M; Lemaire R; Wu MH; Wei J; Taroni J; Harris A; Long KB; Burgwin C; Artlett CM; Blankenhorn EP; Lafyatis R; Varga J; Clark SH; Whitfield ML
    Arthritis Rheumatol; 2016 Aug; 68(8):2003-15. PubMed ID: 26945694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.
    Wei J; Ghosh AK; Chu H; Fang F; Hinchcliff ME; Wang J; Marangoni RG; Varga J
    Arthritis Rheumatol; 2015 May; 67(5):1323-34. PubMed ID: 25707573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling offers insights into the role of innate immune signaling in SSc.
    Johnson ME; Pioli PA; Whitfield ML
    Semin Immunopathol; 2015 Sep; 37(5):501-9. PubMed ID: 26223504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.
    McCoy SS; Reed TJ; Berthier CC; Tsou PS; Liu J; Gudjonsson JE; Khanna D; Kahlenberg JM
    Rheumatology (Oxford); 2017 Nov; 56(11):1970-1981. PubMed ID: 28968684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis.
    Zhou Y; Hou W; Xu K; Han D; Jiang C; Mou K; Li Y; Meng L; Lu S
    Hum Immunol; 2015 Jan; 76(1):22-9. PubMed ID: 25500255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progranulin Promotes Bleomycin-Induced Skin Sclerosis by Enhancing Transforming Growth Factor-β/Smad3 Signaling through Up-Regulation of Transforming Growth Factor-β Type I Receptor.
    Yang T; Zhang X; Chen A; Xiao Y; Sun S; Yan J; Cao Y; Chen J; Li F; Zhang Q; Huang K
    Am J Pathol; 2019 Aug; 189(8):1582-1593. PubMed ID: 31108104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.
    Del Galdo F; Sotgia F; de Almeida CJ; Jasmin JF; Musick M; Lisanti MP; Jiménez SA
    Arthritis Rheum; 2008 Sep; 58(9):2854-65. PubMed ID: 18759267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts.
    Gardner H; Shearstone JR; Bandaru R; Crowell T; Lynes M; Trojanowska M; Pannu J; Smith E; Jablonska S; Blaszczyk M; Tan FK; Mayes MD
    Arthritis Rheum; 2006 Jun; 54(6):1961-73. PubMed ID: 16736506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.